On April 29, 2026 Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported a live webcast at 8:00 AM CET today, Wednesday, 29 April 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presenters: CEO Øystein Soug, CFO Ramzi Amri
Time: 8:00am CET
Webcast link: View Source
Highlights:
Recruited and randomized 37 patients (accumulated, ITT*) into the ovarian Phase 2 trial
Secured new patent expanding protection for Radspherin
Published positive final data from Phase 1 trial of Radspherin to treat ovarian cancer
Journal: Gynecologic Oncology
Conference: ESGO European Gynaecological Oncology Congress 2026
Appointed Dr Ramzi Amri as CFO
The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.
(Press release, Oncoinvent, APR 29, 2026, https://www.oncoinvent.com/press-release/oncoinvent-presents-corporate-update-in-live-webcast/ [SID1234664868])